Novanta/$NOVT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Novanta
Novanta Inc manufactures photonic and motion-control components for original equipment manufacturers in the medical equipment and industrial technology markets. The firm operates in two segments: Automation Enabling Technologies and Medical Solutions. It generates the majority of its revenue from the Medical Solutions segment that designs, manufactures, and markets a range of medical-grade technologies, including medical insufflators, pumps, and related disposables; visualization solutions; and wireless technologies. The firm generates the majority of its revenue from the United States and Europe.
Ticker
$NOVT
Sector
Digital Hardware
Primary listing
Employees
3,000
Headquarters
Website
Novanta Metrics
BasicAdvanced
$4.1B
66.84
$1.69
1.48
-
Price and volume
Market cap
$4.1B
Beta
1.48
52-week high
$179.87
52-week low
$98.76
Average daily volume
376K
Financial strength
Current ratio
2.54
Quick ratio
1.49
Long term debt to equity
62.125
Total debt to equity
64.157
Interest coverage (TTM)
4.84%
Profitability
EBITDA (TTM)
185.46
Gross margin (TTM)
45.08%
Net profit margin (TTM)
6.41%
Operating margin (TTM)
13.36%
Effective tax rate (TTM)
20.54%
Revenue per employee (TTM)
$320,000
Management effectiveness
Return on assets (TTM)
5.49%
Return on equity (TTM)
8.16%
Valuation
Price to earnings (TTM)
66.844
Price to revenue (TTM)
4.25
Price to book
5.07
Price to tangible book (TTM)
-79.25
Price to free cash flow (TTM)
34.502
Free cash flow yield (TTM)
2.90%
Free cash flow per share (TTM)
3.274
Growth
Revenue change (TTM)
6.34%
Earnings per share change (TTM)
-1.74%
3-year revenue growth (CAGR)
6.32%
10-year revenue growth (CAGR)
9.68%
3-year earnings per share growth (CAGR)
-1.72%
10-year earnings per share growth (CAGR)
34.46%
What the Analysts think about Novanta
Analyst ratings (Buy, Hold, Sell) for Novanta stock.
Bulls say / Bears say
Novanta posted GAAP revenue of $241 million for Q2 2025, topping the $238 million consensus, and reported adjusted EPS of $0.76, ahead of the $0.73 estimate. (Reuters)
Bookings rose 10% year-over-year with a book-to-bill ratio of 1.02, underscoring strong demand and backlog momentum. (Reuters)
The Advanced Surgery and Robotics & Automation segments achieved mid-teens percentage revenue growth, demonstrating solid performance in fast-growing markets. (Reuters)
Despite beating estimates, Novanta’s stock dropped 4.81% in pre-market trading, signaling investor concerns about the overall market environment and the company’s valuation, even after the strong results. (Reuters)
Second-quarter revenue growth was mainly fueled by acquisitions and favorable foreign currency movements, indicating that core organic demand remains sluggish. (Reuters)
Full-year 2025 guidance points to only 2–4% revenue growth, while Q3 2025 revenue is expected to be flat or rise just around 1%, reflecting conservative growth prospects. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 1 Sept 2025.
Novanta Financial Performance
Revenues and expenses
Novanta Earnings Performance
Company profitability
Novanta News
AllArticlesVideos
Novanta's Board of Directors Authorizes Additional $200 Million for Share Repurchase Program
Business Wire11 hours ago
Novanta to Present at Baird 2025 Global Healthcare Conference on Tuesday, September 9, 2025
Business Wire1 month ago
Novanta Inc. Schedules Earnings Release and Conference Call for Tuesday, August 5, 2025
Business Wire2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Novanta stock?
Novanta (NOVT) has a market cap of $4.1B as of September 18, 2025.
What is the P/E ratio for Novanta stock?
The price to earnings (P/E) ratio for Novanta (NOVT) stock is 66.84 as of September 18, 2025.
Does Novanta stock pay dividends?
No, Novanta (NOVT) stock does not pay dividends to its shareholders as of September 18, 2025.
When is the next Novanta dividend payment date?
Novanta (NOVT) stock does not pay dividends to its shareholders.
What is the beta indicator for Novanta?
Novanta (NOVT) has a beta rating of 1.48. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.